Photocure ASA · OSL:PHO
Photocure ASA — Bio€quity Europe June 2009
15 slides from Photocure ASA's conference presentation, June 2009
Slide 1: Photocure ASA
Brilliance in photodynamic technology TM Photocure ASA Leadership in photodynamic therapy Bio€quity Europe June 2009 Christian Fekete, CFO
Slide 2: Photocure in brief
Photocure in brief Mission To bring innovative medical therapies to patients worldwide, through efficient development and commercialisation of photodynamic therapy Photocure in brief • Technology based pharmaceutical company listed on OSE • Based on research from Radiumhospitalet • Commercialised tw
Slide 3: Passed important milestones
Passed important milestones Hexvix licensing agreement with First marketing First marketing GE Healthcare approval for approval for Metvix Hexvix Metvix/Aktilite Metvix licensing approved in agreement with the US Galderma Filed first Filed first Hexvix marketing marketing approved in application for
Slide 4: Financial Summary
Financial Summary Numbers in NOK ‘000 (unaudited) Q1 09 Q1 08 FY 2008 FY 2007 NOKm Sales revenue 29 073 21 411 100 917 75 252 Signing fee & milestone revenues 0 1 303 1 309 23 754 Total revenues 29 073 22 713 102 220 99 006 Cost of products sold -4 529 -4 501 -19 074 -17 326 Gross profit 24 545 18 2
Slide 5: Photocure Technology
Photocure Technology™ Photodynamic therapy and diagnosis • Earlier & more accurate diagnosis • More targeted treatment Photoactive • Few/ limited side effects agent Light • Well documented • New standards for diagnosis & treatment of cancer 5
Slide 6: Overview portfolio
Overview portfolio Indication Status Partner Metvix® /Aktilite® Treatment of skin cancer/AK Launched Galderma Launched EU/ Hexvix® Detection of bladder cancer GE Healthcare NDA review US Visonac™ Treatment of acne Phase Il/III Search ongoing Cevira™ Treatment of cervical cancer Phase I/II Search ong
Slide 7: Hexvix - a breakthrough in bladder cancer diagnostics
Brilliance in photodynamic technology TM Hexvix® - a breakthrough in bladder cancer diagnostics
Slide 8: Bladder cancer
Bladder cancer Prevalent, recurring, dangerous and expensive • High prevalence: 5th most common cancer type 3 • Frequent recurrences: In 50%-70% of patients 1 • High mortality: > 50% in advanced cases • Most expensive cancer: USD 96,000-187,000 per patient 2,3 1 Heney NM, et al. Superficial bladder
Slide 9: Hexvix value proposition
Hexvix® value proposition - the only licensed product for fluorescence cystoscopy • Enables doctors to carry out a more effective tumour removal • Strong improvement compared to standard diagnostic procedures Hexvix results Detection of patients w/ bladder cancer 30% more1. Detection of patients w/
Slide 10: The Hexvix opportunity
The Hexvix® opportunity • Large market opportunity in Europe and US: Annual statistics: TURB Operating room • ~ 6 mill cystoscopies • ~ 600,000 procedures (TURBs) Follow-up • > 200,000 new patients 1,2 cystoscopy + Cystoscopy • Targeting a gold standard Out-patient market share in a ~EUR 240 ÷ milli
Slide 11: Research & Development
Brilliance in photodynamic technology TM Research & Development
Slide 12: Summary new products
Summary new products - 3 valuable new indications for proven technology Product Feature Visonac™ Cevira™ Lumacan™ Modality Therapeutic Therapeutic Screening/diagnosis Indication Moderate to severe acne Abnormalities in the cervix Colon cancer (high risk patients) Target peak sales EUR 700 million EU
Slide 13: Progress in the R&D programs
Progress in the R&D programs Clinical Products and Pipeline Explorative Phase I/II Phase IIb Phase III Submission Hexvix ® USA • Preparing for submission to FDA Visonac™ • Preparing for phase III Cevira ™ • Ongoing Proof-of-Concept study in patients with low grade dysplasia Lumacan™ • Ongoing Proof-
Slide 14: Strategic and operational goals
Strategic and operational goals Existing product portfolio - Maximizing values • Metvix®/Aktilite® Support Galderma, follow-up of US development • Hexvix® Seek Hexvix approval in the US • Continue Nordic leadership New products – defined development plan • VisonacTM Seek regulatory advice and start
Slide 15: Investment opportunity
Investment opportunity • Two approved and profitable products • Continuous revenue growth and improving cash flow • Promising pipeline • Large market potential • Well-defined roadmap to market • Strong IP position • Strong balance sheet 15